NeOnc Technologies to Present Updates on Clinical Trials
In a significant development for patients battling malignant brain tumors, NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) has revealed plans to host an investor conference call. This call will take place at an early morning hour and is designed to share crucial data updates regarding their ongoing NEO100-1 Phase 1/2a clinical trial and the compassionate use program for NEO100, an innovative treatment methodology.
Conference Call Details
The conference call is scheduled for Wednesday, November 12, 2025, at 6:00 a.m. Pacific Time and 9:00 a.m. Eastern Time. This timing is strategic, as it occurs prior to market open, allowing investors and stakeholders to absorb the information without distractions. Interested parties can participate in the call via a live webcast, accessible from NeOnc’s investor relations platform.
During this insightful session, key members of the NeOnc management team, alongside independent experts from their Scientific Advisory Board, will present the latest data from the clinical trial. A particular focus will be placed on the progress made regarding NEO100, which is specifically tailored for patients with recurrent high-grade malignant gliomas. Insights into MRI-based radiographic responses and trends in progression-free survival (PFS) and overall survival (OS) will also be provided.
Understanding NEO100
NEO100 is formulated using high-purity perillyl alcohol, harnessed for its brain-penetrant properties, making it a formidable candidate for overcoming the notorious blood-brain barrier. The presentation will also highlight the promising trends observed in clinical outcomes, contributing to the broader understanding of this therapeutic approach.
Featured Participants
The call will include esteemed professionals:
- Dr. Henry S. Friedman, MD – Deputy Director at Duke University’s Preston Robert Tisch Brain Tumor Center.
- Dr. Alexander Miller, MD – Chief of Neuro-oncology at NYU Langone Health.
- The dedicated NeOnc Management Team, featuring:
- Amir Heshmatpour – Chief Executive Officer.
- Dr. Thomas C. Chen, MD, PhD – Chief Medical Officer.
- Dr. Josh Neman, PhD – Chief Clinical Officer.
- Keith Garnett – Chief Financial Officer.
About NeOnc Technologies
NeOnc Technologies is a clinical-stage life sciences company at the forefront of treatment for central nervous system disorders. With a commitment to developing effective therapeutics, NeOnc's innovative NEO™ drug development platform is designed to tackle the challenges of the blood-brain barrier. Their extensive patent portfolio underscores confidence in the potential of therapies like NEO100 and NEO212, both currently in Phase II human clinical trials under FDA Fast-Track and IND status.
This portfolio not only includes significant advancements in treatment methods but also covers a broad range of uses addressing various oncological and neurological conditions. NeOnc has exclusive licenses to an important suite of patents from the University of Southern California, demonstrating strong backing for their ongoing research efforts.
Contact Information
For further inquiries, NeOnc Technologies can be reached at:
Email: info@neonc.com
Investor Relations Contact:
James Carbonara
Hayden IR
Phone: (646)-755-7412
Email: James@haydenir.com
Frequently Asked Questions
What is the purpose of the upcoming conference call?
The conference call is intended to present data updates from NeOnc's ongoing clinical trial for NEO100 and discuss its implications for patient care.
Who will participate in the call?
Members of NeOnc's management team and independent experts from their Scientific Advisory Board will be featured speakers.
What is NEO100?
NEO100 is a proposed treatment for malignant gliomas, utilizing high-purity perillyl alcohol to enhance delivery through the blood-brain barrier.
Where can I access the conference call?
The call can be accessed via a live webcast on NeOnc's investor relations website.
What other therapies are being developed by NeOnc?
In addition to NEO100, NeOnc is advancing the NEO212 therapeutic, both part of their overarching mission to innovate in CNS therapeutics.